MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application

MYND Life Sciences Inc. (CNSX: MYND)(OTCMKTS: MYNDF) is pleased to announce it has completed the National Phase filing of its Patent Cooperation Treaty (PCT) patent application, following on previously submitted provisional patent applications that describe:  “A Method of Immune Modulation by Modulating a Specific Gene.”

MYND’s is profoundly different than the majority of the Psychedelics’ sector. We are seeking intellectual property protection through the pursuit of patents by validation of our Intellectual Property through research and development. As this sector grows and matures and as MYND develops our novel drug development pipeline, the creation of a solid intellectual property portfolio is the key to creating lasting shareholder value. MYND’s ability to obtain patent protection will allow us to move towards the filing of Innovative New Drug (IND) application and approval status.

Dr. Lyle Oberg, MD, CEO of MYND

According to the World Health Organization, over 300,000,000 people globally suffer from depression and other psychiatric disorders. Major Depressive Disorder and Treatment Resistant Depression have a greater than 50% chance of relapse using conventional methods of treatment. Traditional treatments focus solely on symptom suppression, not the root cause. Covid-19 has accelerated the ongoing mental health crisis around the world. In a June 2020 CDC survey, 31% of US respondents reported symptoms of anxiety or depression, 13% started/increased substance use, 26% reported stress-related symptoms, 11% reported serious thoughts of suicide in preceding 30 days. These numbers are double pre-pandemic levels.

The Patent Cooperation Treaty (PCT) is an international treaty with more than 150 Contracting States. The PCT makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single “international” patent application instead of filing several separate national or regional patent applications. The granting of patents remains under the control of the national or regional patent offices in what is called the “national phase”. https://www.uspto.gov/patents/basics/international-protection/patent-cooperation-treaty


MYND has retained Hybrid Financial Ltd. (“Hybrid”) to provide marketing services to the Company. Hybrid has been engaged to heighten market and brand awareness for MYND and to broaden it’s reach within the biotech drug research and development investment community. Hybrid has been engaged for a monthly fee of $22,500 by the Company for an initial period of twelve months, commencing November 16, 2021.

To view the original press release in its entirety click here

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More